Nicholas Erin09.11.2021
2min11685
Tokyo-based VLP Therapeutics Japan announced on October 18 that it plans to begin the final phase of clinical trials in the spring of 2022 and reach mainstream use by the end. The principle of the new vaccine is to use a new replicon technology [a replicon is a piece of DNA capable of autonomous double […]
